ALK-Abelló A/S (ALK-B) - Net Assets
Based on the latest financial reports, ALK-Abelló A/S (ALK-B) has net assets worth Dkr6.45 Billion DKK (≈ $1.01 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr9.17 Billion ≈ $1.44 Billion USD) and total liabilities (Dkr2.73 Billion ≈ $426.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALK-Abelló A/S (ALK-B) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr6.45 Billion |
| % of Total Assets | 70.27% |
| Annual Growth Rate | 0.19% |
| 5-Year Change | 85.2% |
| 10-Year Change | 124.17% |
| Growth Volatility | 17.72 |
ALK-Abelló A/S - Net Assets Trend (2005–2025)
This chart illustrates how ALK-Abelló A/S's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is ALK-Abelló A/S worth.
Annual Net Assets for ALK-Abelló A/S (2005–2025)
The table below shows the annual net assets of ALK-Abelló A/S from 2005 to 2025. Also explore ALK-Abelló A/S net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr6.45 Billion ≈ $1.01 Billion |
+19.95% |
| 2024-12-31 | Dkr5.37 Billion ≈ $840.64 Million |
+20.82% |
| 2023-12-31 | Dkr4.45 Billion ≈ $695.77 Million |
+11.51% |
| 2022-12-31 | Dkr3.99 Billion ≈ $623.95 Million |
+14.60% |
| 2021-12-31 | Dkr3.48 Billion ≈ $544.47 Million |
+10.37% |
| 2020-12-31 | Dkr3.15 Billion ≈ $493.31 Million |
-0.72% |
| 2019-12-31 | Dkr3.18 Billion ≈ $496.91 Million |
-0.09% |
| 2018-12-31 | Dkr3.18 Billion ≈ $497.38 Million |
-3.37% |
| 2017-12-31 | Dkr3.29 Billion ≈ $514.74 Million |
+14.43% |
| 2016-12-31 | Dkr2.88 Billion ≈ $449.81 Million |
+6.60% |
| 2015-12-31 | Dkr2.70 Billion ≈ $421.97 Million |
+14.57% |
| 2014-12-31 | Dkr2.35 Billion ≈ $368.30 Million |
+4.67% |
| 2013-12-31 | Dkr2.25 Billion ≈ $351.87 Million |
-1.53% |
| 2012-12-31 | Dkr2.28 Billion ≈ $357.35 Million |
+5.40% |
| 2011-12-31 | Dkr2.17 Billion ≈ $339.04 Million |
+7.38% |
| 2010-12-31 | Dkr2.02 Billion ≈ $315.73 Million |
+4.67% |
| 2009-12-31 | Dkr1.93 Billion ≈ $301.65 Million |
+3.54% |
| 2008-12-31 | Dkr1.86 Billion ≈ $291.32 Million |
-11.84% |
| 2007-12-31 | Dkr2.11 Billion ≈ $330.44 Million |
+0.86% |
| 2006-12-31 | Dkr2.09 Billion ≈ $327.62 Million |
-66.27% |
| 2005-12-31 | Dkr6.21 Billion ≈ $971.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ALK-Abelló A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 608200000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr6.08 Billion | 94.37% |
| Common Stock | Dkr111.00 Million | 1.72% |
| Other Comprehensive Income | Dkr252.00 Million | 3.91% |
| Total Equity | Dkr6.45 Billion | 100.00% |
ALK-Abelló A/S Competitors by Market Cap
The table below lists competitors of ALK-Abelló A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
$6.06 Billion |
|
Valaris Ltd
NYSE:VAL
|
$6.06 Billion |
|
PT Petrindo Jaya Kreasi Tbk
JK:CUAN
|
$6.06 Billion |
|
Sensata Technologies Holding NV
NYSE:ST
|
$6.06 Billion |
|
Home BancShares Inc
NYSE:HOMB
|
$6.06 Billion |
|
Essential Properties Realty Trust Inc
NYSE:EPRT
|
$6.05 Billion |
|
FirstService Corp
TO:FSV
|
$6.05 Billion |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
$6.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALK-Abelló A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,373,000,000 to 6,445,000,000, a change of 1,072,000,000 (20.0%).
- Net income of 1,197,000,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 187,000,000.
- Other factors decreased equity by 312,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr1.20 Billion | +18.57% |
| Other Comprehensive Income | Dkr187.00 Million | +2.9% |
| Other Changes | Dkr-312.00 Million | -4.84% |
| Total Change | Dkr- | 19.95% |
Book Value vs Market Value Analysis
This analysis compares ALK-Abelló A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.26x to 6.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | Dkr30.70 | Dkr192.30 | x |
| 2006-12-31 | Dkr10.36 | Dkr192.30 | x |
| 2007-12-31 | Dkr10.49 | Dkr192.30 | x |
| 2008-12-31 | Dkr9.32 | Dkr192.30 | x |
| 2009-12-31 | Dkr9.68 | Dkr192.30 | x |
| 2010-12-31 | Dkr10.18 | Dkr192.30 | x |
| 2011-12-31 | Dkr10.95 | Dkr192.30 | x |
| 2012-12-31 | Dkr11.67 | Dkr192.30 | x |
| 2013-12-31 | Dkr11.50 | Dkr192.30 | x |
| 2014-12-31 | Dkr11.92 | Dkr192.30 | x |
| 2015-12-31 | Dkr13.70 | Dkr192.30 | x |
| 2016-12-31 | Dkr14.50 | Dkr192.30 | x |
| 2017-12-31 | Dkr16.51 | Dkr192.30 | x |
| 2018-12-31 | Dkr14.57 | Dkr192.30 | x |
| 2019-12-31 | Dkr14.57 | Dkr192.30 | x |
| 2020-12-31 | Dkr14.34 | Dkr192.30 | x |
| 2021-12-31 | Dkr15.75 | Dkr192.30 | x |
| 2022-12-31 | Dkr18.01 | Dkr192.30 | x |
| 2023-12-31 | Dkr20.10 | Dkr192.30 | x |
| 2024-12-31 | Dkr24.25 | Dkr192.30 | x |
| 2025-12-31 | Dkr29.06 | Dkr192.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ALK-Abelló A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.57%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.96%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.42x
- Recent ROE (18.57%) is above the historical average (9.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 69.69% | 353.49% | 0.18x | 1.12x | Dkr3.68 Billion |
| 2006 | 1.15% | 1.61% | 0.53x | 1.33x | Dkr-185.40 Million |
| 2007 | 8.38% | 10.71% | 0.59x | 1.34x | Dkr-34.20 Million |
| 2008 | 5.10% | 5.33% | 0.70x | 1.36x | Dkr-91.20 Million |
| 2009 | 6.12% | 6.10% | 0.73x | 1.38x | Dkr-74.80 Million |
| 2010 | 6.34% | 5.93% | 0.76x | 1.40x | Dkr-73.80 Million |
| 2011 | 9.23% | 8.52% | 0.70x | 1.55x | Dkr-16.70 Million |
| 2012 | 9.15% | 8.91% | 0.71x | 1.44x | Dkr-19.40 Million |
| 2013 | 2.71% | 2.72% | 0.69x | 1.45x | Dkr-163.90 Million |
| 2014 | 7.69% | 7.44% | 0.71x | 1.45x | Dkr-54.40 Million |
| 2015 | 12.75% | 13.39% | 0.60x | 1.58x | Dkr74.30 Million |
| 2016 | 9.39% | 8.99% | 0.63x | 1.67x | Dkr-17.50 Million |
| 2017 | -4.80% | -5.43% | 0.59x | 1.51x | Dkr-487.00 Million |
| 2018 | -5.35% | -5.83% | 0.60x | 1.53x | Dkr-487.90 Million |
| 2019 | -1.57% | -1.53% | 0.60x | 1.73x | Dkr-367.60 Million |
| 2020 | 0.79% | 0.72% | 0.63x | 1.76x | Dkr-290.30 Million |
| 2021 | 6.29% | 5.59% | 0.67x | 1.68x | Dkr-129.00 Million |
| 2022 | 8.40% | 7.43% | 0.72x | 1.58x | Dkr-63.80 Million |
| 2023 | 10.93% | 10.07% | 0.72x | 1.51x | Dkr41.30 Million |
| 2024 | 15.17% | 14.72% | 0.67x | 1.53x | Dkr277.70 Million |
| 2025 | 18.57% | 18.96% | 0.69x | 1.42x | Dkr552.50 Million |
Industry Comparison
This section compares ALK-Abelló A/S's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $490,285,800
- Average return on equity (ROE) among peers: 0.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALK-Abelló A/S (ALK-B) | Dkr6.45 Billion | 69.69% | 0.42x | $6.06 Billion |
| Bavarian Nordic (BAVA) | $976.29 Million | -4.79% | 0.49x | $2.40 Billion |
| Genmab A/S (GMAB) | $659.52 Million | 17.04% | 1.63x | $20.72 Billion |
| Gubra A/S (GUBRA) | $479.66 Million | -9.28% | 0.30x | $758.45 Million |
| Pharma Equity Group A/S Cl A (PEG) | $-105.44 Million | 0.00% | 0.00x | $15.17 Million |
| Zealand Pharma A/S (ZEAL) | $441.40 Million | 1.54% | 0.06x | $3.05 Billion |
About ALK-Abelló A/S
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more